Lenris 4mg Capsule contains Lenvatinib, a potent multi-kinase inhibitor indicated for the treatment of various malignancies, including differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma. Lenvatinib exerts its therapeutic effect by selectively inhibiting multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, such as VEGFR1-3, FGFR1-4, PDGFRα, RET, and KIT. This inhibition results in reduced tumor vascularization and growth. Lenris 4mg is administered orally and should be taken exactly as prescribed by a healthcare professional. Dosage adjustments may be necessary based on patient tolerance, hepatic function, and adverse event profile. Common adverse effects include hypertension, fatigue, diarrhea, decreased appetite, and proteinuria, which require monitoring throughout treatment. Patients should be advised to report any signs of severe toxicity, including gastrointestinal perforation, hemorrhage, or cardiac dysfunction. Lenris 4mg Capsule is contraindicated in patients with known hypersensitivity to Lenvatinib or any of its excipients. Caution is warranted in patients with pre-existing cardiovascular conditions or impaired hepatic function. Regular clinical and laboratory assessments are essential to optimize therapeutic outcomes and minimize risks. Lenris 4mg Capsule should be stored in a cool, dry place, away from direct sunlight and out of reach of children.